TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Letter to the Editors: Scientists, Media Shouldn’t Overstate “Breakthroughs” May 29, 1998